These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16467680)

  • 81. Antibiotic-loaded plaster of Paris implants coated with poly lactide-co-glycolide as a controlled release delivery system for the treatment of bone infections.
    Benoit MA; Mousset B; Delloye C; Bouillet R; Gillard J
    Int Orthop; 1997; 21(6):403-8. PubMed ID: 9498152
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation.
    Mordenti J; Thomsen K; Licko V; Berleau L; Kahn JW; Cuthbertson RA; Duenas ET; Ryan AM; Schofield C; Berger TW; Meng YG; Cleland J
    Toxicol Sci; 1999 Nov; 52(1):101-6. PubMed ID: 10568703
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis.
    Jaffe GJ; Yang CS; Wang XC; Cousins SW; Gallemore RP; Ashton P
    Ophthalmology; 1998 Jan; 105(1):46-56. PubMed ID: 9442778
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Risk factors, anatomical, and visual outcomes of injured eyes with proliferative vitreoretinopathy: eye injury vitrectomy study.
    Feng K; Hu Y; Wang C; Shen L; Pang X; Jiang Y; Nie H; Wang Z; Ma Z
    Retina; 2013 Sep; 33(8):1512-8. PubMed ID: 23538583
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy.
    La Heij EC; van de Waarenburg MP; Blaauwgeers HG; Kessels AG; Liem AT; Theunissen C; Steinbusch H; Hendrikse F
    Am J Ophthalmol; 2002 Sep; 134(3):367-75. PubMed ID: 12208248
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease.
    Hui YN; Hu D
    Graefes Arch Clin Exp Ophthalmol; 1999 Jul; 237(7):601-5. PubMed ID: 10424311
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effect of slow-releasing all-trans-retinoic acid in bioabsorbable polymer on delayed adjustable strabismus surgery in a rabbit model.
    Lee MJ; Jin SE; Kim CK; Choung HK; Kim HJ; Hwang JM
    Am J Ophthalmol; 2009 Oct; 148(4):566-72. PubMed ID: 19589494
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [The dynamic study of retinoic acid and its alginate sodium microspheres in rabbit eye].
    Wang FX; He SZ; Li XJ; Liang QL; Chen B
    Zhonghua Yan Ke Za Zhi; 2006 Sep; 42(9):814-7. PubMed ID: 17173743
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers.
    Guidetti B; Azéma J; Malet-Martino M; Martino R
    Curr Drug Deliv; 2008 Jan; 5(1):7-19. PubMed ID: 18220546
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A new model of proliferative vitreoretinopathy.
    Frenzel EM; Neely KA; Walsh AW; Cameron JD; Gregerson DS
    Invest Ophthalmol Vis Sci; 1998 Oct; 39(11):2157-64. PubMed ID: 9761295
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Transferrin-ricin A chain toxin limits the development of experimental proliferative vitreoretinopathy.
    Handa JT; Keithahn MA; Jaffe GJ
    Exp Eye Res; 1996 Jun; 62(6):689-96. PubMed ID: 8983950
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial.
    Schaub F; Hoerster R; Schiller P; Felsch M; Kraus D; Zarrouk M; Kirchhof B; Fauser S
    Trials; 2018 Jul; 19(1):384. PubMed ID: 30012187
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo.
    Zheng H; Wang Z; Wang P; Liu Y; Jiang Z; Gao Q
    Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):751-9. PubMed ID: 22119880
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy.
    Zhou T; Lewis H; Foster RE; Schwendeman SP
    J Control Release; 1998 Nov; 55(2-3):281-95. PubMed ID: 9795083
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Evaluation of toxicity and efficacy of a combination of antineoplastic agents in the prevention of PVR.
    Salah-Eldin M; Peyman GA; el-Aswad M; Bandok B; Bahgat MM; Niesman MR
    Int Ophthalmol; 1994; 18(2):53-60. PubMed ID: 7529215
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Intravitreal Tissue Plasminogen Activator Injection for the Treatment of Proliferative Vitreoretinopathy in a Rabbit Model.
    Reitblat O; Barayev E; Gal-Or O; Tsessler M; Dotan A
    Ophthalmic Res; 2023; 66(1):48-56. PubMed ID: 35772382
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Experimental Models to Study Epithelial-Mesenchymal Transition in Proliferative Vitreoretinopathy.
    Datlibagi A; Zein-El-Din A; Frohly M; Willermain F; Delporte C; Motulsky E
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901938
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Modulated release from implantable ocular silicone oil tamponade drug reservoirs.
    Cauldbeck H; Le Hellaye M; McDonald TO; Long M; Williams RL; Rannard SP; Kearns VR
    J Polym Sci A Polym Chem; 2018 Apr; 56(8):938-946. PubMed ID: 29610546
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins.
    Kawahara S; Hata Y; Kita T; Arita R; Miura M; Nakao S; Mochizuki Y; Enaida H; Kagimoto T; Goto Y; Hafezi-Moghadam A; Ishibashi T
    Diabetes; 2008 Oct; 57(10):2784-93. PubMed ID: 18599521
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal drug delivery system of all-trans retinoic acid.
    Dong X; Chen N; Xie L; Wang S
    Retina; 2006 Feb; 26(2):210-3. PubMed ID: 16467680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.